J.P. Morgan Equity Research SA vs UBS IBD SA

First thoughts on this decision? I guess ER would be better for HF exit ops in the long term while IBD is more suited for PE?

Would the J P Morgan name help over UBS regardless of what I wanted to do afterwards?

8 Comments
 

JPM has a very good sell-side ER platform, if we go by II rankings and how many resources they put into their research department (vs. something like GS where they apparently don't give a fuck about their ER franchise). On the other hand, the odds of getting a FT offer for ER post-SA are lower, they run pretty lean.

Under my tutelage, you will grow from boys to men. From men into gladiators. And from gladiators into SWANSONS.
 
Best Response

I would think your options look something like this

ER SA -> ER FT 2/3 years --> HF ER SA -> ER FT 2/3 years --> ER Forever ER SA -> ER FT 2/3 years --> B-School --> HF/PE

&

ER SA -> anything full time

IBD SA ->IBD FT 2 years --> HF/PE/B-School/Pre-Mba roles

While ER does exit to HF, the consensus is that IBD will likely still have an advantage even at most HFs.

If you can take the lifestyle, I would say IBD is always the clear choice for setting up the best exit ops and best chance at a FT offer. Just my opinion.

 
sk8247365I would think your options look something like this

ER SA -> ER FT 2/3 years --> HF ER SA -> ER FT 2/3 years --> ER Forever ER SA -> ER FT 2/3 years --> B-School --> HF/PE

&

ER SA -> anything full time

IBD SA ->IBD FT 2 years --> HF/PE/B-School/Pre-Mba roles

While ER does exit to HF, the consensus is that IBD will likely still have an advantage even at most HFs.

If you can take the lifestyle, I would say IBD is always the clear choice for setting up the best exit ops and best chance at a FT offer. Just my opinion.

I like that breakdown.

Under my tutelage, you will grow from boys to men. From men into gladiators. And from gladiators into SWANSONS.
 

Cum odio inventore veritatis. Sapiente omnis culpa molestiae voluptatibus doloribus modi. Ut explicabo ipsam quae.

Id ut magnam debitis autem. Laborum nostrum consequatur adipisci dolore minus voluptatum. Qui officiis doloribus rerum est qui non. Suscipit dolores rem earum. Repellendus maiores minus dolores aperiam iure eos sit. Voluptas vitae sint distinctio consequatur est.

Alias voluptates aspernatur qui. Quo ut quis ipsum omnis vel praesentium. Quo ullam aliquam rerum. Ullam architecto quo ea quae. Sint cumque animi sit facere.

Career Advancement Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

October 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.4%

Professional Growth Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

October 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”